A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

2.5K views

⸱

DOI:

10.3791/63761

⸱

May 10th, 2022

 ,  ,  ,  , 

In This Article

Summary

We present a protocol to screen anti-hepatitis B virus (HBV) compounds targeting pre- and post-viral entry lifecycle stages, using isothermal titration calorimetry to measure binding affinity (KD) with host sodium taurocholate cotransporting polypeptide. Antiviral efficacy was determined through the suppression of viral lifecycle markers (cccDNA formation, transcription, and viral assembly).

Abstract

Hepatitis B virus (HBV) infection has been considered a crucial risk factor for hepatocellular carcinoma. Current treatment can only lessen the viral load but not result in complete remission. An efficient hepatocyte model for HBV infection would offer a true-to-life viral life cycle that would be crucial for the screening of therapeutic agents. Most available anti-HBV agents target lifecycle stages post viral entry but not before viral entry. This protocol details the generation of a competent hepatocyte model capable of screening for therapeutic agents targeting pre-viral entry and post viral entry lifecycle stages. This includes the targeting of sodium taurocholate cotransporting polypeptide (NTCP) binding, cccDNA formation, transcription, and viral assembly based on imHC or HepaRG as host cells. Here, the HBV entry inhibition assay used curcumin to inhibit HBV binding and transporting functions via NTCP. The inhibitors were evaluated for binding affinity (KD) with NTCP using isothermal titration calorimetry (ITC)-a universal tool for HBV drug screening based on thermodynamic parameters.

Introduction

Hepatitis B virus (HBV) infection is considered a life-threatening disease worldwide. Chronic HBV infection is laden with a risk of liver cirrhosis and hepatocellular carcinoma1. Current anti-HBV treatment focuses mostly on post viral entry using nucleos(t)ide analogs (NAs) and interferon-alpha (IFN-α)2,3. The discovery of an HBV entry inhibitor, Myrcludex B, has identified a novel target for anti-HBV agents4. The combination of entry inhibitors and NAs in chronic HBV has significantly lessened the viral load compared to those targeting viral replication alo....

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: The following procedures must be performed in a Class II biological hazard flow hood or a laminar-flow hood. The handling of HBV was ethically approved by the IRB (MURA2020/1545). See the Table of Materials for details about all solutions, reagents, equipment, and cell lines used in this protocol.

1. Preparing host cells (mature hepatocytes)

  1. Culture hepatocytes (3.75 × 105 cells HepaRG or imHC) and maintain in a 75 cm2 culture flask with 10 mL of DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 100 U/mL penicillin, and 100 µg/m....

Access restricted. Please log in or start a trial to view this content.

Results

Hepatic maturation features were observed, including binucleated cells and polygonal-shaped morphology (Figure 1), especially in the differentiated stage of imHC (Figure 1A). A large increase in NTCP expression was measured in d-HepaRG and d-imHC at 7-fold and 40-fold, respectively (Figure 1B). The highly glycosylated form of NTCP, postulated to confer susceptibility to HBV entry, was detected more in d-imHC than in d-HepaRG (

Access restricted. Please log in or start a trial to view this content.

Discussion

HBV infection is initiated via low-affinity binding to heparan sulfate proteoglycans (HSPGs) on hepatocytes25, followed by the binding to NTCP with subsequent internalization through endocytosis26. As NTCP is a crucial receptor for HBV entry, targeting HBV entry can be clinically translated to diminish de novo infection, mother-to-child transmission (MTCT), and recurrence after liver transplantation. Interrupting viral entry would be a feasible alternative cure for.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgements

This research project is supported by Mahidol University and the Thailand Science Research and Innovation (TSRI) separately awarded to A. Wongkajornsilp and K. Sa-ngiamsuntorn. This work was financially supported by the Office of National Higher Education Science Research and Innovation Policy Council through the Program Management Unit for Competitiveness (grant number C10F630093). A. Wongkajornsilp is a recipient of a Chalermprakiat grant of the Faculty of Medicine Siriraj Hospital, Mahidol University. The authors would like to thank Miss Sawinee Seemakhan (Excellent Center for Drug Discovery, Faculty of Science, Mahidol University) for her assistance with the ITC t....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Cell lines
HepaRG Cells, CryopreservedThermo Fisher ScientificHPRGC10
Hep-G2/2.2.15 Human Hepatoblastoma Cell LineMerckSCC249
Reagents
4% Paraformadehyde Phosphate Buffer SolutionFUJIFLIM Wako chemical163-20145
BD Perm/Wash bufferBD Biosciences554723Perm/Wash buffer
Cyclosporin Aabcam59865-13-3
EDTAInvitrogen15575-0388 mM
G 418 disulfate saltMerck108321-42-2
Halt Protease Inhibitor Cocktail  EDTA-free (100x)Thermo Scientific78425
HEPESMerck7365-45-9
illustraTM RNAspin Mini RNA isolation kitsGE Healthcare25-0500-71
illustra RNAspin Mini RNA Isolation KitGE Healthcare25-0500-71
ImProm-II Reverse Transcription SystemPromegaA3800
KAPA SYBR FAST qPCR KitKapa BiosystemsKK4600
Lenti-X ConcentratorTakara bioPT4421-2concentrator
Luminata crescendo Western HRP substrateMerckWBLUR0100
Master Mix (2x) UniversalKapa BiosystemsKK4600
Nucleospin DNA extraction kitmacherey-nagel1806/003
Phosphate buffered salineMerckP3813
Polyethylene glycol 8000Merck25322-68-3
ProLong Gold Antifade MountantThermo scientificP36930
Recombinant NTCPCloud-CloneRPE421Hu02
RIPA Lysis Buffer (10x)Merck20-188
TCASigma345909-26-4
TCA Elisa kitMybiosourceMB2033685
Triton X-100Merck9036-19-5
Trypsin-EDTAGibco25200072Dilute to 0.125%
Antibodies
    Anti-NTCP1 antibodyAbcamab1310841:100 dilution
    Anti-GAPDH antibodyThermo Fisher ScientificAM43001:200,000 dilution
   HRP-conjugated goat anti-rabbit antibodyAbcamab2057181:10,000 dilution
   HRP goat anti-mouse secondary antibodyAbcamab970231:10,000 dilution
   Goat anti-Rabbit IgG Secondary Antibody, Alexa Fluor 488InvitrogenA-110081:500 dilution
Reagent composition
1° Antibody dilution buffer
     1x TBST
     3% BSASigmaA7906-100GWorking concentration: 3%
     Sodium azideSigma199931Working concentration: 0.05%
Hepatocyte Growth Medium
      DME/F12Gibco12400-024
      10% FBSSigma AldrichF7524
      1% Pen/StrepHyClonSV30010
      1% GlutaMAXGibco35050-061
Hepatic maturation medium
      Williams’ E mediumSigma AldrichW4125-1L
      10% FBSSigma AldrichF7524
      1% Pen/StrepHyClonSV30010
      1% GlutaMAXGibco35050-061
      5 µg/mL  InsulinSigma Aldrich91077C-100MG
      50 µM hydrocotisoneSigma AldrichH0888-1g
     2% DMSOPanReac AppliChemA3672-250ml
IF Blocking solution
     1x PBSGibco21300-058
     3% BSASigmaA7906-100GWorking concentration: 3%
     0.2% Triton X-100SigmaT8787Working concentration: 0.2%
RIPA Lysis Buffer SolutionMerck20-188Final concentration: 1X
     Protease Inhibitor CocktailThermo Scientific78425Final concentration: 1X
       Na3VO4Final concentration: 1 mM
       PMSFFinal concentration: 1 mM
       NaFFinal concentration: 10 mM
Western blot reagent
     10x Tris-buffered saline (TBS)Bio-Rad170-6435Final concentration: 1X
     Tween 20Merck9005-64-5
     1x TBST0.1% Tween 20
     1x PBSGibco21300-058
     Pierce BCA Protein Assay KitThermo Fisher ScientificA53225
     Polyacrylamide gelBio-Rad161-0183
     Ammonium Persulfate (APS)Bio-Rad161-0700Final concentration: 0.05%
    TEMEDBio-Rad161-0800Stacker gel: 0.1%, Resolver gel: 0.05%
    2x Laemmli Sample BufferBio-Rad161-0737Final concentration: 1X
    Precision Plus Protein Dual Color StandardsBio-Rad161-0374
WB Blocking solution/ 2° Antibody dilution buffer
     1x TBST
     5% Skim milk (nonfat dry milk)Bio-Rad170-6404Working concentration: 5%
1x Running buffer 1 L
      10x Tris-buffered saline (TBS)Bio-Rad170-6435Final concentration: 1X
     GlycineSigmaG889814.4 g
     SDSMerck7910Working concentration: 0.1%
Blot transfer buffer 500 mL
      10x Tris-buffered saline (TBS)Bio-Rad170-6435Final concentration: 1X
     GlycineSigmaG88987.2 g
     MethanolMerck106009100 mL
Mild stripping solution 1 LAdjust pH to 2.2
    GlycineSigmaG889815 g
     SDSMerck79101 g
     Tween 20Merck9005-64-510 mL
Equipments
15 mL centrifuge tubeCorning430052
50 mL centrifuge tubeCorning430291
Airstream Class IIEsco2010621Biological safety cabinet
CelCulture CO2 IncubatorEsco2170002Humidified tissue culture incubator
CFX96 Touch Real-Time PCR DetectorBio-Rad1855196
FACSVerse Flow CytometerBD Biosciences651154
Graduated pipettes (10 mL)Jet BiofilGSP010010
Graduated pipettes (5 mL)Jet BiofilGSP010005
MicroCal PEAQ-ITCMalvernIsothermal titration calorimeters
Mini PROTEAN Tetra CellBio-Rad1658004Electrophoresis chamber
Mini Trans-blot absorbent filter paperBio-Rad1703932
Omega Lum G Imaging SystemAplegen8418-10-0005
Pipette controllerEppendorf4430000.018Easypet 3
PowerPac HCBio-Rad1645052Power supply
PVDF membraneMerckIPVH00010
T-75 cell culture flaskCorning431464U
Trans-Blot SD Semi-Dry Transfer CellBio-Rad1703940Semi-dry transfer cell
Ultrasonic processor (Vibra-Cell VCX 130)Sonics & Materials
Versati Tabletop Refrigerated CentrifugeEscoT1000RCentrifuge with swinging bucket rotar

References

  1. Levrero, M., Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatology. 64 (1), 84-101 (2016).
  2. Kim, K. -H., Kim, N. D., Seong, B. -L. Discovery and development of anti-HBV agents and their resistance. Molecules. 15 (9), 5878-5908 (20....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

NTCP BindingViral Entry InhibitionFlow CytometryIsothermal Titration CalorimetryTaurocholic Acid UptakeImmunofluorescence StainingHepaRG CellsPolymerase Chain Reaction